These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 35930599)
1. Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma. Qu C; Wang C; Li H; Li Y; Han C; Tao X; Guan X; Zhang Y; Chen M; Liu J; Zou W Cell Biol Int; 2022 Nov; 46(11):1759-1774. PubMed ID: 35930599 [TBL] [Abstract][Full Text] [Related]
2. A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells. Zhang XT; Kang LG; Ding L; Vranic S; Gatalica Z; Wang ZY Oncogene; 2011 Feb; 30(7):770-80. PubMed ID: 20935677 [TBL] [Abstract][Full Text] [Related]
3. The location of estrogen receptor variant ER-α36 is associated with the invasion of glioblastoma. Li H; Ge N; Guan X; Han C; Li Y; Shen L; Chen M; Zhang B; Qu C; Zou W Steroids; 2023 Jun; 194():109224. PubMed ID: 36924815 [TBL] [Abstract][Full Text] [Related]
4. Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells. Zhang XT; Ding L; Kang LG; Wang ZY Oncol Rep; 2012 Jun; 27(6):2057-65. PubMed ID: 22426783 [TBL] [Abstract][Full Text] [Related]
5. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells. Zhang X; Deng H; Wang ZY J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581 [TBL] [Abstract][Full Text] [Related]
6. The ER-α36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells. You H; Meng K; Wang ZY Steroids; 2018 Jun; 134():78-87. PubMed ID: 29481815 [TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor variant ER-α36 promotes tamoxifen agonist activity in glioblastoma cells. Qu C; Ma J; Zhang Y; Han C; Huang L; Shen L; Li H; Wang X; Liu J; Zou W Cancer Sci; 2019 Jan; 110(1):221-234. PubMed ID: 30417588 [TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. Zhang X; Ding L; Kang L; Wang ZY PLoS One; 2012; 7(1):e30174. PubMed ID: 22276155 [TBL] [Abstract][Full Text] [Related]
9. ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway. Zhu L; Zou J; Zhao Y; Jiang X; Wang Y; Wang X; Chen B J Exp Clin Cancer Res; 2018 Jun; 37(1):123. PubMed ID: 29940998 [TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer. Wang ZY; Yin L Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453 [TBL] [Abstract][Full Text] [Related]
11. ER-α36 mediates estrogen-stimulated MAPK/ERK activation and regulates migration, invasion, proliferation in cervical cancer cells. Sun Q; Liang Y; Zhang T; Wang K; Yang X Biochem Biophys Res Commun; 2017 Jun; 487(3):625-632. PubMed ID: 28435071 [TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324 [TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells. Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129 [TBL] [Abstract][Full Text] [Related]
14. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells. Kang L; Guo Y; Zhang X; Meng J; Wang ZY J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803 [TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772 [TBL] [Abstract][Full Text] [Related]
16. ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway. Tong JS; Zhang QH; Wang ZB; Li S; Yang CR; Fu XQ; Hou Y; Wang ZY; Sheng J; Sun QY PLoS One; 2010 Nov; 5(11):e15408. PubMed ID: 21079811 [TBL] [Abstract][Full Text] [Related]
17. The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors. Gu Y; Chen T; López E; Wu W; Wang X; Cao J; Teng L J Transl Med; 2014 Jan; 12():16. PubMed ID: 24447535 [TBL] [Abstract][Full Text] [Related]
18. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha. Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634 [TBL] [Abstract][Full Text] [Related]
19. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Kang L; Zhang X; Xie Y; Tu Y; Wang D; Liu Z; Wang ZY Mol Endocrinol; 2010 Apr; 24(4):709-21. PubMed ID: 20197310 [TBL] [Abstract][Full Text] [Related]
20. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]